Search Results - "Lopera FS" :: Library Catalog

Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1^Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.

Authors: Tariot PN Lopera FS Ríos-Romenets S et al.

Source: The Lancet. Neurology [Lancet Neurol] 2026 Feb; Vol. 25 (2), pp. 147-159.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE

Search Results - "Lopera FS"

Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.

Search Tools:

Refine Results

Format

Source

Year of Publication

Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1^Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.